RECRUITING

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.

Official Title

Alteration of the Immune Microenvironment in Basal Cell Carcinoma (BCC) Following Photodynamic Therapy (PDT)

Quick Facts

Study Start:2021-12-13
Study Completion:2027-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05020912

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic
  2. * Must have at least one BCC tumor eligible for removal by surgical excision
  3. * Men and women of any ethnic group are eligible
  4. * Must provide informed consent to participate
  1. * Pregnant or breastfeeding
  2. * Currently being treated for other cancers with medical or radiation therapy
  3. * Known hypersensitivity to 5-aminolevulinic acid (ALA)
  4. * History of a photosensitivity disease, e.g.,porphyria cutanea tarda

Contacts and Locations

Study Contact

Edward V Maytin, MD, PhD
CONTACT
216-444-5139
maytine@ccf.org

Principal Investigator

Edward V Maytin, MD, PhD
PRINCIPAL_INVESTIGATOR
Cleveland Clinic, Case Comprehensive Cancer Center

Study Locations (Sites)

Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195
United States

Collaborators and Investigators

Sponsor: Case Comprehensive Cancer Center

  • Edward V Maytin, MD, PhD, PRINCIPAL_INVESTIGATOR, Cleveland Clinic, Case Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-12-13
Study Completion Date2027-12

Study Record Updates

Study Start Date2021-12-13
Study Completion Date2027-12

Terms related to this study

Additional Relevant MeSH Terms

  • Basal Cell Carcinoma